Instem plc Issue of Equity and Total Voting Rights (4128I)
December 08 2015 - 10:53AM
UK Regulatory
TIDMINS
RNS Number : 4128I
Instem plc
08 December 2015
Instem plc
("Instem", the "Company" or the "Group")
Issue of Equity and Total Voting Rights
Instem plc (AIM: INS), a leading provider of IT solutions to the
global early development healthcare market, announces that,
following the exercise of vested EMI share options by an employee,
10,000 ordinary shares of 10p each in the Company ("Ordinary
Shares") have been issued.
Application will be made to the London Stock Exchange for the
admission of the 10,000 new Ordinary Shares to trading on AIM.
Admission is expected to take place at 8.00am on 9 December
2015.
Total Voting Rights
Following the issue and allotment of the above new Ordinary
Shares, the Company's issued share capital comprises 13,043,774
Ordinary Shares. The Company does not hold any Ordinary Shares in
treasury. Therefore the total number of voting rights in the
Company is 13,043,774.
The figure of 13,043,774 may be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change of their
interest in, the Company under the FCA's Disclosure and
Transparency Rules.
For further information, please contact:
Instem plc +44 (0) 1785 825 600
Phil Reason, CEO
Nigel Goldsmith, CFO
N+1 Singer (Nominated
Adviser & Broker) +44 (0) 20 7496 3000
Richard Lindley
Nick Owen
Walbrook Financial PR +44 (0) 20 7933 8000
Paul Cornelius instem@walbrookpr.com
Helen Cresswell
Sam Allen
About Instem plc
Instem is a leading supplier of IT applications to the early
development healthcare market, delivering compelling solutions for
data collection, management and analysis across the R&D
continuum. Instem applications are in use by customers worldwide,
meeting the rapidly expanding needs of life science and healthcare
organisations for data-driven decision making leading to safer,
more effective products.
Instem's portfolio of software solutions increases client
productivity by automating study-related processes while offering
the unique ability to generate new knowledge through the extraction
and harmonisation of actionable scientific information.
Instem supports over 400 clients through full service offices in
the United States, the United Kingdom, India and China, with
additional presence in France and Japan.
To learn more about Instem solutions and its mission, please
visit www.instem.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEASAPESESFFF
(END) Dow Jones Newswires
December 08, 2015 10:53 ET (15:53 GMT)
Instem (LSE:INS)
Historical Stock Chart
From Jul 2024 to Aug 2024
Instem (LSE:INS)
Historical Stock Chart
From Aug 2023 to Aug 2024